R&D
JP Morgan 2024 – Sam Deutsch

JP Morgan 2024 – Sam Deutsch

In another lightning round JP Morgan interview, editor-in-chief Jonah Comstock caught up with Sam Deutsch, CEO of Nutcracker Therapeutics, to talk briefly about the company’s lead asset for cervica

R&D
JP Morgan interview with Jonah Comstock and Marianne De Backer

JP Morgan 2024 – Marianne De Backer

Vir Biotechnology made headlines in 2021 for its work with GlaxoSmithKline on a treatment for COVID-19, and again in 2022 for its work with the US government on influenza.

Digital
JP Morgan 2024 – Simon Arkell interviewed by Jonah Comstock

JP Morgan 2024 – Simon Arkell

Generative AI – large language models, or LLMs, like ChatGPT – has the potential to revolutionise almost any knowledge industry, and pharma is no exception.

R&D
JP Morgan 2024 – Katherine Stueland and Jonah Comstock

JP Morgan 2024 – Katherine Stueland

Diagnostics can be a neglected part of the treatment paradigm, but it’s hugely important for connecting patients with the right treatments.

R&D
Jonah Comstock and Frank Gleeson at JP Morgan

JP Morgan 2024 – Frank Gleeson

In this brief dispatch from JP Morgan, editor-in-chief Jonah Comstock grabs a few minutes with Frank Gleeson, CEO of Satellos Bioscience.

Digital

Digital
JP Morgan 2024 – Simon Arkell interviewed by Jonah Comstock

JP Morgan 2024 – Simon Arkell

Generative AI – large language models, or LLMs, like ChatGPT – has the potential to revolutionise almost any knowledge industry, and pharma is no exception.

Market Access

Market Access
Health Innovators – Aleks Engel

Health Innovators – Aleks Engel

One month ago, editor-in-chief Jonah Comstock travelled to Copenhagen, Denmark to visit the Novo Nordisk Foundation.

Market Access
Health Innovators – Søren Møller

Health Innovators – Søren Møller

Søren Møller, managing partner for seed investments at Novo Holdings, believes successful start-ups in healthcare share a trifecta of component pieces: “great science, the right talent, and

Oncology

Oncology
CAR-TCR 2023 – Jonathan Wofford

CAR-TCR 2023 – Jonathan Wofford

In order for cell therapies to scale effectively, the industry is clamouring for standardisation around things like manufacturing and treatment administration.

Oncology
CAR-TCR 2023 – Mindy Miller

CAR-TCR 2023 – Mindy Miller

As more cell therapies are approved and the category emerges, there’s also an increased need for the technology that enables cell therapy development.

Newsletters and Deep Dive
digital magazine

Patients

R&D
Health Innovators Cytokinetics

Health Innovators – Fady Malik and Steve Heitner

In this instalment of Health Innovators, EiC Jonah Comstock sits down virtually with Fady Malik, EVP of research and development at Cytokinetics and Steve Heitner, the company’s VP of clinical rese

Digital
Reuters Pharma USA Maria Whitman

Reuters Pharma USA – Maria Whitman

For decades, the pharma industry has been building commercialisation models that put field reps at the heart of the engagement equation.

R&D

R&D
JP Morgan 2024 – Sam Deutsch

JP Morgan 2024 – Sam Deutsch

In another lightning round JP Morgan interview, editor-in-chief Jonah Comstock caught up with Sam Deutsch, CEO of Nutcracker Therapeutics, to talk briefly about the company’s lead asset for cervica

R&D
JP Morgan interview with Jonah Comstock and Marianne De Backer

JP Morgan 2024 – Marianne De Backer

Vir Biotechnology made headlines in 2021 for its work with GlaxoSmithKline on a treatment for COVID-19, and again in 2022 for its work with the US government on influenza.